These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152 [TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322 [TBL] [Abstract][Full Text] [Related]
5. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery. Tomita E; Takase H; Tajima K; Suematsu Y Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794 [TBL] [Abstract][Full Text] [Related]
6. [The use of recombinant activated factor VIIa for major bleedings in open heart surgery]. Ingimarsson JP; Onundarson PT; Valsson F; Vidarsson B; Gudbjartsson T Laeknabladid; 2008 Sep; 94(9):607-12. PubMed ID: 18784387 [TBL] [Abstract][Full Text] [Related]
7. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pychyńska-Pokorska M; Moll JJ; Krajewski W; Jarosik P Pediatr Crit Care Med; 2004 May; 5(3):246-50. PubMed ID: 15115562 [TBL] [Abstract][Full Text] [Related]
8. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII. Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247 [TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Raivio P; Suojaranta-Ylinen R; Kuitunen AH Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342 [TBL] [Abstract][Full Text] [Related]
10. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications. Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023 [TBL] [Abstract][Full Text] [Related]
11. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. Uber WE; Toole JM; Stroud MR; Haney JS; Lazarchick J; Crawford FA; Ikonomidis JS J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1469-77.e2. PubMed ID: 21457998 [TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy. von Heymann C; Redlich U; Jain U; Kastrup M; Schroeder T; Sander M; Grosse J; Ziemer S; Koscielny J; Konertz WF; Wernecke KD; Spies C Crit Care Med; 2005 Oct; 33(10):2241-6. PubMed ID: 16215377 [TBL] [Abstract][Full Text] [Related]
13. Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery? Okonta KE; Edwin F; Falase B Interact Cardiovasc Thorac Surg; 2012 Oct; 15(4):690-4. PubMed ID: 22811512 [TBL] [Abstract][Full Text] [Related]
14. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage. Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674 [TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Chapman AJ; Blount AL; Davis AT; Hooker RL Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468 [TBL] [Abstract][Full Text] [Related]
16. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Guzzetta NA; Huch S; Fernandez JD; Tosone SR; Miller BE Paediatr Anaesth; 2009 Apr; 19(4):364-70. PubMed ID: 19143947 [TBL] [Abstract][Full Text] [Related]
17. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. Rao VK; Lobato RL; Bartlett B; Klanjac M; Mora-Mangano CT; Soran PD; Oakes DA; Hill CC; van der Starre PJ J Cardiothorac Vasc Anesth; 2014 Oct; 28(5):1221-6. PubMed ID: 25281040 [TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457 [TBL] [Abstract][Full Text] [Related]
19. Recombinant activated factor VII use in critically ill infants with active hemorrhage. Jen H; Shew S J Pediatr Surg; 2008 Dec; 43(12):2235-8. PubMed ID: 19040942 [TBL] [Abstract][Full Text] [Related]
20. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Guzzetta NA; Russell IA; Williams GD Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]